TABLE OF CONTENT: 1. Introduction 1.1. Research Scope 1.2. Market Segmentation 1.3. Research Methodology 1.4. Definitions and Assumptions 2. Executive Summary 3. Market Dynamics 3.1. Market Drivers 3.2. Market Restraints 3.3. Market Opportunities 4. Key Insights 4.1 Prevalence of Non Small CellLung Cancer by Type 4.2 Regulatory Scenario by KeyRegions 4.3 Key Industry Developments 4.4 Pipeline Analysis 4.5 Overview of Current Advances in R&D for Non Small Cell Lung Cancer Therapeutics 5. Global Non SmallCell Lung Cancer Therapeutics Market Analysis, Insights and Forecast, 2015-2026 5.1. Key Findings / Summary 5.2. Market Analysis, Insightsand Forecast – By Therapy 5.2.1 Targeted Therapy 5.2.1.1 Bevacizumab 5.2.1.2 Dabrafenib/Trametinib 5.2.1.3 Erlotinib Hydrochloride 5.2.1.4 Osimertinib 5.2.1.5 Others 5.2.2 Immunotherapy 5.2.2.1 Durvalumab 5.2.2.2 Nivolumab 5.2.2.3 Atezolizumab 5.2.2.4 Pembrolizumab 5.2.3 Chemotherapy 5.3. Market Analysis, Insights and Forecast – By Distribution Channel 5.3.1 Hospital Pharmacies 5.3.2 Retail Pharmacies 5.3.3 Online Pharmacies 5.3.4 Others 5.4 Market Analysis, Insights and Forecast – By Cancer Type 5.4.1 Adenocarcinoma 5.4.2 Squamous Cell Carcinoma 5.4.3 Large Cell Carcinoma 5.5. Market Analysis, Insights and Forecast – By Region 5.5.1 North America 5.5.2 Europe 5.5.3 Asia Pacific 5.5.4 Latin America 5.5.5 Middle East & Africa 6. North America Non Small Cell Lung Cancer Therapeutics Market Analysis, Insights and Forecast,2015-2026 6.1. Key Findings / Summary 6.2. Market Analysis – By Therapy 6.2.1 Targeted Therapy 6.2.1.1 Bevacizumab 6.2.1.2 Dabrafenib/Trametinib 6.2.1.3 ErlotinibHydrochloride 6.2.1.4 Osimertinib 6.2.1.5 Others 6.2.2 Immunotherapy 6.2.2.1 Durvalumab 6.2.2.2 Nivolumab 6.2.2.3 Atezolizumab 6.2.2.4 Pembrolizumab 6.2.3 Chemotherapy 6.3. Market Analysis – By Distribution Channel 6.3.1 Hospital Pharmacies 6.3.2 Retail Pharmacies 6.3.3 Online Pharmacies 6.3.4 Others 6.4. Market Analysis – By Cancer Type 6.4.1 Adenocarcinoma 6.4.2 Squamous Cell Carcinoma 6.4.3 Large Cell Carcinoma 6.5. Market Analysis – By Country 6.5.1 U.S. 6.5.2 Canada 7. Europe Non Small Cell Lung Cancer Therapeutics Market Analysis, Insights and Forecast, 2015-2026 7.1. Key Findings / Summary 7.2. Market Analysis – By Therapy 7.2.1 Targeted Therapy 7.2.1.1 Bevacizumab 7.2.1.2 Dabrafenib/Trametinib 7.2.1.3 Erlotinib Hydrochloride 7.2.1.4 Osimertinib 7.2.1.5 Others 7.2.2 Immunotherapy 7.2.2.1 Durvalumab 7.2.2.2 Nivolumab 7.2.2.3 Atezolizumab 7.2.2.4 Pembrolizumab 7.2.3 Chemotherapy 7.3. Market Analysis – By Distribution Channel 7.3.1 Hospital Pharmacies 7.3.2 Retail Pharmacies 7.3.3 Online Pharmacies 7.3.4 Others 7.4. Market Analysis – By Cancer Type 7.4.1 Adenocarcinoma 7.4.2 Squamous Cell Carcinoma 7.4.3 Large Cell Carcinoma 7.5. Market Analysis – By Country/Sub-region 7.5.1 Germany 7.5.2 U.K. 7.5.3 France 7.5.4 Italy 7.5.5 Spain 7.5.6S candinavia 7.5.7 Rest of Europe 8. Asia Pacific Non Small Cell Lung Cancer Therapeutics Market Analysis, Insights and Forecast,2015-2026 8.1. Key Findings / Summary 8.2. Market Analysis – By Therapy 8.2.1 Targeted Therapy 8.2.1.1 Bevacizumab 8.2.1.2 Dabrafenib/Trametinib 8.2.1.3 Erlotinib Hydrochloride 8.2.1.4 Osimertinib 8.2.1.5 Others 8.2.2 Immunotherapy 8.2.2.1 Durvalumab 8.2.2.2 Nivolumab 8.2.2.3 Atezolizumab 8.2.2.4 Pembrolizumab 8.2.3 Chemotherapy 8.3. Market Analysis – By Distribution Channel 8.3.1 Hospital Pharmacies 8.3.2 Retail Pharmacies 8.3.3 Online Pharmacies 8.3.4 Others 8.4. Market Analysis – By Cancer Type 8.4.1 Adenocarcinoma 8.4.2 Squamous Cell Carcinoma 8.4.3 Large Cell Carcinoma 8.5. Market Analysis – By Country/ Sub-region 8.5.1 China 8.5.2 India 8.5.3 Japan 8.5.4 Australia 8.5.5 Southeast Asia 8.5.6 Rest of Asia Pacific 9. Latin America Non Small Cell Lung Cancer Therapeutics Market Analysis, Insights and Forecast,2015-2026 9.1. Key Findings / Summary 9.2. Market Analysis – By Therapy 9.2.1 Targeted Therapy 9.2.1.1 Bevacizumab 9.2.1.2 Dabrafenib/Trametinib 9.2.1.3 Erlotinib Hydrochloride 9.2.1.4 Osimertinib 9.2.1.5 Others 9.2.2 Immunotherapy 9.2.2.1 Durvalumab 9.2.2.2 Nivolumab 9.2.2.3 Atezolizumab 9.2.2.4 Pembrolizumab 9.2.3 Chemotherapy 9.3. Market Analysis – By Distribution Channel 9.3.1 Hospital Pharmacies 9.3.2 Retail Pharmacies 9.3.3 Online Pharmacies 9.3.4 Others 9.4. Market Analysis – By Cancer Type 9.4.1 Adenocarcinoma 9.4.2 Squamous Cell Carcinoma 9.4.3 Large Cell Carcinoma 9.5. Market Analysis – By Country/ Sub-Region 9.5.1 Brazil 9.5.2 Mexico 9.5.3 Rest of Latin America 10. Middle East &Africa Non Small Cell Lung Cancer Therapeutics Market Analysis, Insights and Forecast, 2015-2026 10.1. Key Findings / Summary 10.2. Market Analysis – By Therapy 10.2.1 Targeted Therapy 10.2.1.1 Bevacizumab 10.2.1.2 Dabrafenib/Trametinib 10.2.1.3 Erlotinib Hydrochloride 10.2.1.4 Osimertinib 10.2.1.5 Others 10.2.2 Immunotherapy 10.2.2.1 Durvalumab 10.2.2.2 Nivolumab 10.2.2.3 Atezolizumab 10.2.2.4 Pembrolizumab 10.2.3 Chemotherapy 10.3. Market Analysis – By Distribution Channel 10.3.1 Hospital Pharmacies 10.3.2 Retail Pharmacies 10.3.3 Online Pharmacies 10.3.4 Others 10.4. Market Analysis – By Cancer Type 10.4.1 Adenocarcinoma 10.4.2 Squamous Cell Carcinoma 10.4.3 LargeCell Carcinoma 10.5. Market Analysis – By Country/ Sub-region 10.5.1 South Africa 10.5.2 GCC Countries 10.5.3 Rest of Middle East & Africa 11. Competitive Analysis 11.1. Key Industry Developments 11.2. Global Market Share Analysis (2018) 11.3. Competition Dashboard 11.4. Comparative Analysis –Major Players 11.5. Company Profiles (Overview,Products & services, SWOT analysis, Recent developments, strategies,financials (based on availability)) 11.5.1 Genentech, Inc. (F. Hoffmann-La Roche Ltd) 11.5.2 EliLilly and Company 11.5.3 CelgeneCorporation 11.5.4 AstraZeneca 11.5.5 PfizerInc. 11.5.6 Sanofi 11.5.7 Novartis AG 11.5.8 Astellas Pharma Inc. 11.5.9 Bristol-Myers Squibb Company 11.5.10 Boehringer Ingelheim Pharmaceuticals, Inc. 11.5.11 Millennium Pharmaceuticals, Inc. (Takeda) 11.5.12 Merck Sharp & Dohme Corp. 11.5.13 Other Prominent Players 12. Strategic Recommendations

Genentech (F. Hoffmann-La Roche Ltd) Eli Lilly and Company Celgene Corporation AstraZeneca Pfizer Inc. Sanofi Novartis AG Astellas Bristol Myers Squibb Boehringer Ingelheim Pharmaceuticals, Inc. Millennium Pharmaceuticals, Inc. (Takeda) Merck Sharp & Dohme Corp. Other players